In aggressive prostate cancers, the efficacy of the AKT inhibitor AZD5363 is limited, and blocking autophagy using 3-MA, CQ, and Baf A1 enhanced cell death (Lamoureux et al., 2013). The gene discussed is AKT1; the disease is prostate cancer.